✦ LIBER ✦

2.277 OPTIMIZATION OF PHASE III STUDY DESIGN FOR PIMAVANSERIN IN THE TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS (PDP)

✍ Scribed by R. Mills; D. Bahr; H. Williams

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antipsychotic efficacy and good tolerabi

✍ Ballard, Clive; Mills, Roger; Williams, Hilde; Chi-Burris, Kathy; Bahr, Daun; Cu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Antipsychotic efficacy and motor tolerab

✍ Cummings, J.; Isaacson, S.; Mills, R.; Williams, H.; Chi-Burris, K.; Dhall, R.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Challenges of phase III trial design for

✍ Fenaux, Pierre; Seymour, John F.; Santini, Valeria; Silverman, Lew; Gore, Steven 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 492 KB

Su1085 Reduction of Fecal Calprotectin a

✍ D'Haens, Geert R.; Sandborn, William; Colombel, Jean-Frederic; Brown, Kurt; Havi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 861 KB

DOP059 Reduction of fecal calprotectin l

✍ D'Haens, G.; Sandborn, W.J.; Rutgeerts, P.; Colombel, J.F.; Brown, K.; Haviv, A. 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 52 KB

The US Multicenter Double-Blind, Randomi

✍ T.J Schroeder; L.W Moore; L.W Gaber; A.O Gaber; M.R First 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 77 KB